These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 2092151

  • 1. Breast cancer mucin antigen (BCM) determination by IMX: a preliminary study of epidemiological distribution of the serum levels in gynecological diseases.
    Torre GC, Barbetti V, Lanfranco E, Robutti M, Foglia M, Corongiu F, Vigliercio GP.
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):59-62. PubMed ID: 2092151
    [No Abstract] [Full Text] [Related]

  • 2. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
    van Dalen A, Kessler AC.
    Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
    [Abstract] [Full Text] [Related]

  • 3. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
    Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A, Lichtenegger W.
    Anticancer Res; 2003 Apr; 23(2A):1115-8. PubMed ID: 12820357
    [Abstract] [Full Text] [Related]

  • 4. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
    Fernández Llana B, Fernández Fernández M, Suárez B, Allende MT.
    Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
    [No Abstract] [Full Text] [Related]

  • 5. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U, Baumgartner L, Stieber P, Meier W, Hofmann K, Fateh-Moghadam A.
    Anticancer Res; 1994 Mar; 14(6B):2743-6. PubMed ID: 7532929
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of squamous cell carcinoma antigen (SCC-A) in Egyptian gynecologic cancer patients.
    Salman T, el-Ahmady O, Tony O, Darwish M.
    Anticancer Res; 1997 Mar; 17(4B):3083-6. PubMed ID: 9329607
    [Abstract] [Full Text] [Related]

  • 7. [Experiences with the cancer marker CA 125 in gynecologic diseases].
    Pilgrim G, von Broen B, Johannsmeyer KD.
    Z Gesamte Inn Med; 1989 Apr 15; 44(8):251-4. PubMed ID: 2741520
    [Abstract] [Full Text] [Related]

  • 8. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV, Skvortsov SV, Lytsar BN, Khomenko LP.
    Klin Med (Mosk); 1993 Apr 15; 71(2):25-7. PubMed ID: 8046917
    [Abstract] [Full Text] [Related]

  • 9. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC, Artner-Dworzak E, Schröcksnadel H, Müller-Holzner E, Daxenbichler G, Heim K.
    Gynakol Rundsch; 1989 Apr 15; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract] [Full Text] [Related]

  • 10. MCA performance in preoperative breast cancer patients.
    Donadeo A, Micelli G, Quaranta M, Atlante A, Schittulli F.
    Anticancer Res; 1995 Apr 15; 15(2):527-9. PubMed ID: 7763034
    [Abstract] [Full Text] [Related]

  • 11. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
    Devine PL, McGuckin MA, Ramm LE, Harada H, Ward BG.
    Cancer Biochem Biophys; 1993 Sep 15; 13(4):221-38. PubMed ID: 8521372
    [Abstract] [Full Text] [Related]

  • 12. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T, Schürenkämper P, Minguillon C, Lichtenegger W.
    Anticancer Res; 1997 Sep 15; 17(4B):2953-4. PubMed ID: 9329573
    [Abstract] [Full Text] [Related]

  • 13. [Serum BCM in patients with nontumorous diseases. Preliminary results].
    Allende MT, Vizoso F, Sampedro A, Ruibal A.
    Rev Clin Esp; 1990 Oct 15; 187(5):254-5. PubMed ID: 2102542
    [No Abstract] [Full Text] [Related]

  • 14. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
    Cappellari A, Bagarella M, Corradi G.
    Boll Ist Sieroter Milan; 1990 Oct 15; 69(1):315-8. PubMed ID: 2102115
    [Abstract] [Full Text] [Related]

  • 15. [CA50].
    Kawabe T.
    Nihon Rinsho; 2005 Aug 15; 63 Suppl 8():645-6. PubMed ID: 16149601
    [No Abstract] [Full Text] [Related]

  • 16. Clinical use of gynaecologic tumour markers.
    Halila H, Alfthan H, Stenman UH.
    Ann Chir Gynaecol; 1989 Aug 15; 78(1):65-70. PubMed ID: 2547331
    [Abstract] [Full Text] [Related]

  • 17. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR, Beason KL, Bryant S, Johnson JT, Jackson M, Wilson C, Holifield K, Vincent C, Hall M.
    Biomed Sci Instrum; 2003 Aug 15; 39():408-14. PubMed ID: 12724928
    [Abstract] [Full Text] [Related]

  • 18. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M, Hippeläinen M, Kettunen J, Salmela E, Penttilä I, Alhava E.
    Anticancer Res; 1994 Aug 15; 14(2B):699-703. PubMed ID: 8010729
    [Abstract] [Full Text] [Related]

  • 19. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
    Rodríguez CA, Cruz JJ, Martín T, Gómez A, Olaverri A, Hernández M.
    Cancer; 2002 Aug 01; 95(3):670-1; author reply 671. PubMed ID: 12209762
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of MCA and CA 15-3 in tissue and in serum of patients with breast carcinoma: preliminary results.
    Reale G, Giovagnoli MR, Vecchione A, Cosentino L, Benci F, Manna A, Marchei G, Vittori I, Frati L.
    J Nucl Med Allied Sci; 1990 Aug 01; 34(4 Suppl):53. PubMed ID: 2092150
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.